PRODUCT

Thymosin Alpha-1 (5 mg Vial)

No short description available.

Quickstart Highlights

Thymosin Alpha-1 (Tα1) is a 28–amino acid peptide originally isolated from the thymus gland, recognized for its broad immunomodulatory properties[1]. It has been investigated as an immune enhancer in chronic viral infections (hepatitis B/C, HIV/AIDS) and critical illness (sepsis, COVID-19)[2][3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
Typical daily range: 300–500 mcg once daily (gradual titration).
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate and use within 7 days.

Molecular Info

Chain Length:28 amino acids
Sequence Type:Acetylated polypeptide
Molecular Weight:3,108 Da
Amino Acid Sequence:Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
Modification:N-terminal acetylated synthetic peptide identical to naturally occurring thymic hormone

Research Indications

Immunity

moderate

Primary Immunodeficiencies
FDA orphan drug designation for DiGeorge syndrome with documented restoration of T-cell function and immune competence.
Vaccine Response Enhancement
Enhances immunogenicity in elderly and immunocompromised patients with improved antibody responses.
HIV/AIDS Immune Support
Restores CD4+ T-cell counts and reduces opportunistic infections with sustained immunological improvement.

Inflammation

effective

Cytokine Storm Mitigation
Reduces pro-inflammatory cytokines by 40-60% while maintaining balanced immune responses.
Chronic Inflammatory Conditions
Modulates inflammatory responses in hepatitis, pancreatitis, and autoimmune conditions.

Recovery

effective

Post-Surgical Immune Recovery
Accelerates immune system recovery following major surgery or chemotherapy through lymphocyte restoration.
Exercise-Induced Immunosuppression
Counters stress-induced immune suppression in athletes and high-stress situations.

Anti Aging

most_effective

Thymic Regeneration
Supports age-related thymic decline through hormone replacement therapy in elderly populations.
Immune Senescence Prevention
Delays age-related immune deterioration with improved vaccine responses.

Cellular

effective

Antioxidant Enzyme Enhancement
Increases antioxidant enzyme activity providing cellular protection against oxidative damage.
Mitochondrial Function Support
Supports cellular energy metabolism and protects against age-related mitochondrial decline.

Reconstitution

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Interactions

Immunosuppressive Agents

Contraindicated

Absolute contraindication in organ transplant recipients. Fatal immune hemolytic anemia and graft rejection documented in hematopoietic stem cell transplant patients.

Corticosteroids

Monitor Combination

Pharmacodynamic antagonism as Ta1 blocks steroid-induced thymocyte apoptosis, potentially reducing immunosuppressive effects.

Interferon-α

Synergistic

Enhanced antiviral efficacy in hepatitis treatment with synergistic NK cell activation. Monitor for increased fever, fatigue, and neutropenia.

Vaccines

Compatible

Intended therapeutic effect enhancing vaccine immunogenicity, particularly beneficial in elderly and immunocompromised patients.

Chemotherapy Agents

Compatible

Protective effects against cytotoxic bone marrow damage while maintaining standard oncology monitoring protocols.

Protocol Overview

Goal:Support immune modulation and enhance host defense mechanisms[1][2].
Schedule:Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range:300–500 mcg daily with gradual titration.
Reconstitution:3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
Storage:Lyophilized refrigerated or frozen; reconstituted refrigerated; use within 7 days.

Dosage Protocols

Start:300 mcg daily for Week 1 to assess tolerance.
Target:500 mcg daily from Week 2 onward.
Frequency:Once per day (subcutaneous).
Cycle Length:8–12 weeks; optional extension to 16 weeks.
Timing:Any consistent time; rotate injection sites.

Dosage Protocols

Standard immune support:1.6mg2x weekly
Acute conditions (sepsis):1.6mg2x daily × 5 days, then daily
Cancer/hepatitis support:1.6mg2x weekly
Maintenance/prevention:1.6mg2x weekly

Route:injectable

Storage Instructions

Lyophilized:Store at 2–8 °C (35.6–46.4 °F) for short-term or −20 °C (−4 °F) for long-term; minimize moisture exposure[5].
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days when using bacteriostatic water; avoid freeze–thaw.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
Inspect solution before each use—do not use if cloudy or discolored.

Reconstitution

Clean work area and hands thoroughly
Add 1.0 mL sterile water slowly to lyophilized powder
Inject water slowly down vial side (not directly onto powder)
Gently swirl until completely dissolved (never shake)
Final concentration: 1.6 mg/mL
Use promptly or refrigerate at 2-8°C for up to 7 days

Route:injectable

How It Works

Thymosin Alpha-1 is a naturally occurring thymic peptide that modulates immune function through multiple pathways[1]. It enhances the maturation and differentiation of T‑cells, augments dendritic cell function, and promotes the production of key cytokines including interferon‑α and interleukin‑2[2][6]. Clinical studies have demonstrated Tα1’s ability to enhance immune responses in immunocompromised individuals, including those with chronic hepatitis B and C infections[4]. Meta-analyses have also shown benefit in reducing mortality in moderate-to-critical COVID-19 patients[3].

Lifestyle Factors

Maintain adequate sleep and stress management to support immune function.
Consume a nutrient‑dense diet rich in vitamins C, D, and zinc.
Engage in moderate physical activity to complement immune optimization.
Avoid excessive alcohol and smoking, which impair immune responses.

Injection Technique

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[9][10].
Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[11].

Benefits and Side Effects

Benefits

Supports enhanced T‑cell function and overall immune competence[1][2].
Demonstrates an excellent safety profile; doses up to 1.6 mg twice weekly for 6–12 months have been well-tolerated[4][7].
Even at experimental doses up to 16 mg SC over 12 months, no significant Tα1‑specific toxicity has been observed[7].

Side Effects

Most common adverse effect is mild injection‑site irritation (redness or discomfort).

Thymosin Alpha-1 (5 mg Vial)

Resources

Categories

Company